Wockhardt Limited (BOM:532300)

Market Cap	226.64B +9.4%
Revenue (ttm)	30.07B +0.9%
Net Income	-230.00M
EPS	-1.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,276
Average Volume	37,443
Open	1,365.15
Previous Close	1,381.90
Day's Range	1,364.85 - 1,433.55
52-Week Range	1,109.60 - 1,870.00
Beta	n/a
RSI	51.31
Earnings Date	Feb 10, 2026

About Wockhardt

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an anti...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 2,296
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532300

Financial Performance

In fiscal year 2025, Wockhardt's revenue was 30.35 billion, an increase of 7.24% compared to the previous year's 28.30 billion. Losses were -470.00 million, -89.85% less than in 2024.